Payment overview · 2025
General Payments
$646.19
36 reported records · 17 companies
Healthcare provider profile · identity verified
David K Booth, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, IN · NPI 1144250689
Verified facts
What the public records show
CMS Open Payments records show David K Booth, D.O. received $646.19 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.61 | 14.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.47 | 12.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.12 | 9.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $55.97 | 8.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.29 | 7.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.18 | 7.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.02 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.53 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.60 | 4.4% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.42 | 4.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.49 | 3.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.48 | 3.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.17 | 3.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.59 | 3.2% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $17.22 | 2.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.39 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.64 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $646.19 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.06 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.12 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $55.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.29 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.18 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.07 | 3 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $17.22 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 40 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 206 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
70 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
206 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 939 | 250 |
| Levothyroxine Sodium | Levothyroxine Sodium | 683 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 637 | 181 |
| Lisinopril | Lisinopril | 632 | 170 |
| Losartan Potassium | Losartan Potassium | 460 | 141 |
| Gabapentin | Gabapentin | 454 | 122 |
| Omeprazole | Omeprazole | 438 | 127 |
| Metformin Hcl | Metformin Hcl | 359 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 98 |
| Simvastatin | Simvastatin | 320 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 300 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 279 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 234 | 55 |
| Sertraline Hcl | Sertraline Hcl | 226 | 63 |
| Metformin Hcl Er | Metformin Hcl | 215 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 61 |
| Ozempic | Semaglutide | 206 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 200 | 62 |
| Trazodone Hcl | Trazodone Hcl | 190 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 188 | 55 |
| Montelukast Sodium | Montelukast Sodium | 187 | 56 |
| Alendronate Sodium | Alendronate Sodium | 159 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 37 |
| Jardiance | Empagliflozin | 151 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 41 |
| Tramadol Hcl | Tramadol Hcl | 146 | 37 |
| Eliquis | Apixaban | 145 | 36 |
| Meloxicam | Meloxicam | 143 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 39 |
| Allopurinol | Allopurinol | 136 | 41 |
| Furosemide | Furosemide | 133 | 50 |
| Januvia | Sitagliptin Phosphate | 128 | 37 |
| Potassium Chloride | Potassium Chloride | 128 | 36 |
| Ezetimibe | Ezetimibe | 121 | 35 |
| Glipizide Er | Glipizide | 118 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 34 |
| Xarelto | Rivaroxaban | 109 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 28 |
| Methocarbamol | Methocarbamol | 104 | 22 |
| Famotidine | Famotidine | 101 | 27 |
| Prednisone | Prednisone | 100 | 74 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 28 |
| Pregabalin | Pregabalin | 96 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 30 |
| Valsartan | Valsartan | 95 | 29 |
| Atenolol | Atenolol | 94 | 30 |
| Buspirone Hcl | Buspirone Hcl | 93 | 33 |
| Carvedilol | Carvedilol | 92 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 20 |
| Finasteride | Finasteride | 90 | 28 |
| Alprazolam | Alprazolam | 88 | 22 |
| Glimepiride | Glimepiride | 88 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 29 |
| Trulicity | Dulaglutide | 88 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 17 |
| Spironolactone | Spironolactone | 83 | 26 |
| Donepezil Hcl | Donepezil Hcl | 81 | 16 |
| Clonazepam | Clonazepam | 79 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 35 |
| Mirtazapine | Mirtazapine | 77 | 23 |
| Mounjaro | Tirzepatide | 76 | 15 |
| Synthroid | Levothyroxine Sodium | 72 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 70 | 60 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 65 | 65 |
| Torsemide | Torsemide | 65 | 11 |
| Celecoxib | Celecoxib | 63 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 20 |
| Cephalexin | Cephalexin | 61 | 48 |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 57 | 18 |
| Warfarin Sodium | Warfarin Sodium | 57 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 51 |
| Clonidine Hcl | Clonidine Hcl | 55 | 17 |
| Lovastatin | Lovastatin | 52 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 14 |
| Lorazepam | Lorazepam | 50 | 16 |
| Azithromycin | Azithromycin | 49 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 14 |
| Benazepril Hcl | Benazepril Hcl | 48 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 13 |
| Tradjenta | Linagliptin | 45 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Naproxen | Naproxen | 43 | 16 |
| Belsomra | Suvorexant | 42 | suppressed |
| Irbesartan | Irbesartan | 42 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 24 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 40 |
| Aripiprazole | Aripiprazole | 40 | 11 |
| Baclofen | Baclofen | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 27 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 26 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Lidocaine | Lidocaine | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nystatin | Nystatin | 31 | 19 |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | 11 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 22 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $646.19 · 36 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Azstarys, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Flector, GARDASIL 9, INGREZZA, Jornay PM, Licart, OTEZLA, Ohtuvayre, Ozempic, PENBRAYA, PREVNAR 20, REPATHA, Saxenda, TRELEGY ELLIPTA, TRUMENBA, The Cologuard Plus Collection Kit, Tirosint, VAXNEUVANCE, VRAYLAR, Wegovy, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error